December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Intravitreal Injection of Triamcinolone in the Treatment of Refractory Cystoid Maular Edema
Author Affiliations & Notes
  • M Spirn
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • DB Roth
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • DL Yarian
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • SN Green
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • SR Leff
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • ES Friedman
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • BJ Keyser
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • HM Wheatley
    Retina Vitreous Center Robert Wood Johnson Medical School New Brunswick NJ
  • Footnotes
    Commercial Relationships   M. Spirn, None; D.B. Roth, None; D.L. Yarian, None; S.N. Green, None; S.R. Leff, None; E.S. Friedman, None; B.J. Keyser, None; H.M. Wheatley, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 501. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M Spirn, DB Roth, DL Yarian, SN Green, SR Leff, ES Friedman, BJ Keyser, HM Wheatley; Intravitreal Injection of Triamcinolone in the Treatment of Refractory Cystoid Maular Edema . Invest. Ophthalmol. Vis. Sci. 2002;43(13):501.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To study the effect of intravitreal injection of triamcinolone as treatment for chronic cystoid macular edema (CME) refractory to drops or periocular steroid injections. Method: Twenty nine eyes of 23 patients were treated. The visual acuity before treatment ranged from 20/40 to 20/400. All patients were evaluated with pre-treatment fluorecein angiography (FA). The degree of cystoid macular edema, as well as the amount of diffuse macular edema was graded on a scale of 0 to 4. The etiology of the CME was diabetic retinopathy in nineteen eyes, macular pucker in three eyes, postoperative CME in five eyes, central retinal vein occlusion in one eye, and idiopathic in one eye. Treatment consisted of a single intravitreal injection of 1 mg of triamcinolone under sterile conditions. A paracentesis was performed if the intraocular pressure was above 40 mm Hg after injection. Several patients required repeat trimacinolone injections over follow-up for persistent or recurrent leakage from CME on fluorescein angiography. Results: CME diminished or resolved completely in 26 (89.7%) of 29 eyes. Visual acuity improved by 2 or more lines of Snellen visual acuity in 6 (20.7%) eyes and remained the same in 23 (79.3%) eyes. None of the patients experienced visual loss over the initial follow-up period. Fourteen (48.3%) of the 29 eyes improved by one or more lines of Snellen visual acuity. Conclusion: Intravitreal injection of triamcinolone appears to be an effective treatment modality for refractory cystoid macular edema. Repeat injections may be necessary to address persistent or recurrent CME. The lasting effect of this treatment needs further study with longer follow-up.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 387 diabetes • 460 macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×